completed

TRANSCEND is a parallel study (with ONTARGET) comparing the effects of Telmisartan with placebo and outcomes in patients at high risk for cardiovascular events and intolerant to ACE-I.

TRANSCEND was a large, simple, randomized, double-blind, multicentre, international trial.

Primary endpoints:

  • Cardiovascular death
  • Non-fatal myocardial infarction
  • Non-fatal stroke
  • Hospitalization for congestive heart failure (CHF).

Secondary endpoints:

  • Newly diagnosed CHF
  • CV revascularization procedures
  • Newly diagnosed diabetes
  • Cognitive decline (adjudication done by a special committee)
  • New onset of atrial fibrillation, nephropathy

All primary and secondary endpoints were adjudicated.

Study Type

Interventional - Drug

Study Design

Parallel group double-blind

NO. of Countries

40

NO. of Sites

650

NO. of Participants

5926

Study Period

2001-2008

Sponsor

Boehringer Ingelheim

Boehringer Ingelheim

Back To Top